Drug · DIN 02512173
COPAXONE
PREFILLED PENS
Authorized, not yet reported as sold
Authorized for sale in Canada; the company has not yet told Health Canada that it is on the market.
Status Approved since February 4, 2021.
- Drug Identification Number (DIN)
- 02512173
- Company (DIN owner)
- Teva Canada LimitedToronto, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Solution
- Route
- Subcutaneous
- Therapeutic class (ATC)
- Glatiramer acetate L03AX13
- Class
- Human
- Record last updated
- August 14, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| GLATIRAMER ACETATE | 40 MG | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- February 4, 2021: NOC 25152Supplement to a New Drug Submission (SNDS) · Addition of 40 mg/ml pre-filled pen
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “copaxone”. A notice may cover another product or only some lots: read it to see what it covers.
- Important Safety Information on COPAXONE (glatiramer acetate) and the Risk of Anaphylactic Reactions Which May Occur at Any Time Following Initiation of TreatmentAugust 21, 2025 · Drugs · New safety information - Product safety - Adverse reaction
Other DINs named COPAXONE
- DIN 02245619 · Marketed
- DIN 02456915 · Marketed
- DIN 02233014 · Cancelled Post Market